Nektar

Nektar Therapeutics has announced topline results from its Phase 2b REZOLVE-AA trial evaluating rezpegaldesleukin (REZPEG) in patients with severe-to-very-severe alopecia areata (AA). The data establish clinical proof of concept and support advancement into Phase 3 development, positioning rezpegaldesleukin as a potential non-JAK option for this autoimmune hair-loss condition. What is Rezpegaldesleukin? Rezpegaldesleukin is a first-in-class…